Compugen (NASDAQ:CGEN) Upgraded at Zacks Investment Research

Compugen (NASDAQ:CGEN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday, Zacks.com reports. The firm presently has a $4.50 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price target would suggest a potential upside of 7.91% from the company’s previous close.

According to Zacks, “Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen’s expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. “

Separately, ValuEngine lowered shares of Compugen from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd.

NASDAQ:CGEN opened at $4.17 on Thursday. Compugen has a 12-month low of $2.00 and a 12-month high of $4.50. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.38 and a quick ratio of 5.38. The firm has a 50-day moving average price of $4.09 and a 200 day moving average price of $3.68.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.04. As a group, equities analysts anticipate that Compugen will post -0.45 EPS for the current year.

Large investors have recently bought and sold shares of the stock. Wells Fargo & Company MN raised its position in Compugen by 424.5% in the second quarter. Wells Fargo & Company MN now owns 7,526 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 6,091 shares in the last quarter. LPL Financial LLC acquired a new position in Compugen in the second quarter worth about $43,000. D. E. Shaw & Co. Inc. acquired a new position in Compugen in the second quarter worth about $45,000. Royal Bank of Canada raised its position in Compugen by 115.4% in the second quarter. Royal Bank of Canada now owns 57,500 shares of the biotechnology company’s stock worth $221,000 after purchasing an additional 30,800 shares in the last quarter. Finally, Jane Street Group LLC raised its position in Compugen by 20.5% in the second quarter. Jane Street Group LLC now owns 65,721 shares of the biotechnology company’s stock worth $252,000 after purchasing an additional 11,192 shares in the last quarter. 29.95% of the stock is owned by hedge funds and other institutional investors.

Compugen Company Profile

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.

Featured Story: Dow Jones Industrial Average (DJIA)

Get a free copy of the Zacks research report on Compugen (CGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.